Stentys has raised US$18 million
Stentys has raised US$18 million through private equity investment.
Stentys develops a new-generation stent designed for treatment of acute myocardial infarction and coronary artery bifurcations. Based in Princeton, New Jersey, and Paris, France, the company intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure.
Oaklins’ team in France advised Stentys on its two financing rounds, raising a total of US$18 million. The team continues to advise Stentys on corporate strategic matters.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreDolmans Landscaping Group has welcomed Foreman Capital as a new shareholder to support further growth
Dolmans Landscaping Group, a leading full-service provider of landscaping services, has welcomed Foreman Capital as a new shareholder. By partnering with Foreman Capital, which has extensive experience in building stronger companies in the maintenance of public spaces, Dolmans can accelerate its growth trajectory across core verticals and further professionalize the business.
Learn moreTyler Grange has been acquired by Fidelio
Tyler Grange has been acquired by Fidelio, a Swedish growth-oriented investor. Backed by Fidelio, it has become a founding member of Myllium, a newly formed international collective of nature and sustainability specialists.
Learn more